Keyword: Vir Biotechnology
Brii Biosciences is expanding on existing partnerships and inking a new deal with VBI Vaccines that could be worth up to $128.5 million.
Bringing innovative, clinically differentiated medicines to Chinese patients.
Octave Biosciences picked up a pair of industry veterans for its board of directors, as well as $14 million to advance its care management technology.
Otsuka plans to acquire Visterra and its antibody engineering platform for $430 million in cash, as it aims to build out its discovery efforts.
Decibel Therapeutics raised $55 million in a series C round and named Vir Biotechnology CEO George Scangos as chair of its board of directors.
Alta Partners raised $130 million for its ninth venture capital fund, focusing on biotech and healthcare technology companies.
SoftBank is considering a $150 million investment in siteless trial runner Science 37, the latest in a string of biotech deals, according to reports.
Novartis Oncology head Bruno Strigini retires, Amneal poaches Allergan's Robert Stewart, plus more hirings, firings and retirings across the industry.
CSO Hayden will leave as Teva restructures, Bayer R&D reorg sees Moeller in and Busch out for Shire, Shire and Biogen get experienced CFOs.
Vir Biotech CEO Geroge Scangos has lined up infectious disease and immunology expert Skip Virgin from Washington University as its new R&D head.